Ponesimod

CHEMBL1096146 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

461.0 g/mol

LogP

4.6

Phase

4

Used to reduce the frequency of relapses and slow the progression of disability in adults with relapsing forms of multiple sclerosis by trapping certain immune cells in lymph nodes, preventing them from reaching the brain and spinal cord where they cause damage. It is taken as a daily tablet with a gradual dose-escalation schedule to minimize heart rate effects.

Masse moléculaire

461,0000 g/mol

LogP

4,60

TPSA

108,00 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Psoriasis Multiple Sclerosis

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C

InChI

InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23-/t17-/m1/s1

Molecular Formula

C23H25ClN2O4S

HBD / HBA

2 / 6

Liaisons Rotatives

8

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

Used to reduce the frequency of relapses and slow the progression of disability in adults with relapsing forms of multiple sclerosis by trapping certain immune cells in lymph nodes, preventing them from reaching the brain and spinal cord where they cause damage. It is taken as a daily tablet with a gradual dose-escalation schedule to minimize heart rate effects.

Yes, Ponesimod is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1096146. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 11363176. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Ponesimod sur PillFYI

Structure

Données Clés

Formule: C23H25ClN2O4S
Synonymes: 1

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.